X0306 4 2020-03-16 0 0001672619 IMARA Inc. IMRA 0001734389 Chin Mark 20 BERKELEY SQUARE MAYFAIR, LONDON X0 W1J 6EQ UNITED KINGDOM 1 0 1 0 Common Stock 2020-03-16 4 C 0 1367058 A 1367058 I By entities affiliated with Arix Bioscience plc Common Stock 2020-03-16 4 P 0 187500 16.00 A 1554558 I By entities affiliated with Arix Bioscience plc Series B Preferred Stock 2020-03-16 4 C 0 8611110 0.00 D Common Stock 1367058 0 I By entities affiliated with Arix Bioscience plc Stock Option (right to buy) 16.00 2020-03-16 4 A 0 15457 0.00 A 2030-03-15 Common Stock 15457 15457 D On March 16, 2020, the Issuer's Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. The reporting person is a member of the Investment Committee of Arix and shares voting and dispositive power over the shares held by Arix. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of all of the reported shares for purposes of Section 16 or any other purpose. The option vests in three equal installments on March 16, 2021, 2022 and 2023. /s/ Michael P. Gray, Attorney-in-Fact 2020-03-16